| Form N-CSR Cover | 12 Months Ended |
| Dec. 31, 2024 | |
| Shareholder Report [Line Items] | |
| Document Type | N-CSR |
| Amendment Flag | false |
| Registrant Name | T. ROWE PRICE EQUITY SERIES, INC. |
| Entity Central Index Key | 0000918294 |
| Entity Investment Company Type | N-1A |
| Document Period End Date | Dec. 31, 2024 |
| Shareholder Report | 12 Months Ended |
| Dec. 31, 2024 USD ($) Holding | |
| Shareholder Report [Line Items] | |
| Document Type | N-CSR |
| Amendment Flag | false |
| Registrant Name | T. ROWE PRICE EQUITY SERIES, INC. |
| Entity Central Index Key | 0000918294 |
| Entity Investment Company Type | N-1A |
| Document Period End Date | Dec. 31, 2024 |
| C000005448 | |
| Shareholder Report [Line Items] | |
| Fund Name | Health Sciences Portfolio |
| Class Name | Health Sciences Portfolio Class |
| Trading Symbol | QAAGZX |
| Shareholder Report Annual or Semi-Annual | Annual Shareholder Report |
| Additional Information [Text Block] | You can find the fund’s prospectus, financial information on Form N‑CSR (which includes required tax information for dividends), holdings, proxy voting information, and other information at www.troweprice.com/prospectus info troweprice.com |
| Material Fund Change Notice [Text Block] | |
| Additional Information Phone Number | 1‑800‑638‑5660 |
| Additional Information Email | info@troweprice.com</span>" id="sjs-B19"><span style="box-sizing: border-box; color: rgb(0, 0, 0); display: inline; flex-wrap: nowrap; font-size: 13.3333px; font-weight: 400; grid-area: auto; line-height: 17.3333px; margin: 0px; overflow: visible; text-align: justify;">info@troweprice.com</span> |
| Additional Information Website | www.troweprice.com/prospectus |
| Expenses [Text Block] | What were the fund costs for the last year? Costs of a $10,000 investment Costs paid as a percentage of a $10,000 investment Health Sciences Portfolio Class $89 0.88% |
| Expenses Paid, Amount | $ 89 |
| Expense Ratio, Percent | 0.88% |
| Factors Affecting Performance [Text Block] | What drove fund performance during the past 12 months? The health care sector posted solid advances in the first nine months of 2024; however, these returns were diminished in the fourth quarter, leaving the group with modest gains for the year. The products and devices subsector was a bright spot as a handful of growth companies with exciting new product cycles led the segment higher. Despite facing heightened concerns around increased regulatory uncertainty at the end of the period, the pharmaceuticals segment was boosted by significant demand for a new class of diabetes and weight-loss drugs. The services subsector was the laggard in the space, largely driven by utilization pressures and heightened negative sentiment around the managed care industry. From an absolute perspective, the leading contributor to performance was the portfolio’s significant position in Eli Lilly. Shares of the pharmaceutical giant benefited from strong demand and improvements in capacity for its portfolio of incretin medicines, alongside several positive regulatory developments. Conversely, the leading detractor from absolute performance was Elevance Health. Shares of the insurer traded sharply lower at the end of the period due to multiple factors, including (1) a challenging Medicaid environment driving an uptick in utilization, (2) uncertainty around the health care agenda of the incoming presidential administration, and (3) worsening public sentiment toward the managed care space following the tragic murder of an industry executive. Our overarching investment philosophy remains focused on innovation, and we believe companies that are producing leading‑edge therapeutics and medical devices offer some of the market’s most attractive growth areas for investors with a multiyear horizon. |
| Performance Past Does Not Indicate Future [Text] | The fund’s past performance is not a good predictor of the fund’s future performance. |
| Average Annual Return [Table Text Block] | Average Annual Total Returns 1 Year 5 Years 10 Years Health Sciences Portfolio (Health Sciences Portfolio Class) 1.66 % 6.08 % 8.47 % Russell 3000 Index (Regulatory Benchmark) 23.81 13.86 12.55 Russell 3000 Health Care Index (Strategy Benchmark) 3.48 7.18 8.81 S&P 500 Index (Previous Benchmark) 25.02 14.53 13.10 The preceding line graph shows the value of a hypothetical $10,000 investment in the fund over the past 10 fiscal year periods or since inception (for funds lacking 10-year records). The fund’s performance information included in the line graph and table above is compared with a regulatory required index that represents an overall securities market (Regulatory Benchmark). In addition, the line graph and table may also include one or more indexes that more closely aligns to the fund's investment strategy (Strategy Benchmark(s)). Due to new SEC Rules on shareholder reporting the fund adopted a new broad-based securities market index, referred to as the Regulatory Benchmark. Market index returns do not include expenses, which are deducted from fund returns. The fund's total return figures reflect the reinvestment of dividends and capital gains, if any.Neither the fund’s returns nor the index returns reflect the deduction of taxes that a shareholder would pay on fund distributions or redemptions of fund shares. The fund’s past performance is not a good predictor of the fund’s future performance. |
| No Deduction of Taxes [Text Block] | Neither the fund’s returns nor the index returns reflect the deduction of taxes that a shareholder would pay on fund distributions or redemptions of fund shares. |
| Performance Table Market Index Changed [Text Block] | Due to new SEC Rules on shareholder reporting the fund adopted a new broad-based securities market index, referred to as the Regulatory Benchmark. |
| Updated Performance Information Location [Text Block] | Updated performance information can be found at www.troweprice.com. |
| Distribution of Capital [Text Block] | The fund's total return figures reflect the reinvestment of dividends and capital gains, if any. |
| AssetsNet | $ 664,924,000 |
| Holdings Count | Holding | 274 |
| Advisory Fees Paid, Amount | $ 5,427,000 |
| InvestmentCompanyPortfolioTurnover | 49.90% |
| Additional Fund Statistics [Text Block] | What are some fund statistics? Fund Statistics Total Net Assets (000s) $664,924 Number of Portfolio Holdings 274 |
| Holdings [Text Block] | Industry Other Biotechnology 27.4 % Major Pharmaceuticals 17.1 Implants 14.9 Life Sciences 10.9 Payors 10.9 Other Products & Devices 6.6 Major Biotechnology 6.5 Providers 1.8 Distribution 0.9 Other 3.0 |
| Largest Holdings [Text Block] | Top Ten Holdings Eli Lilly 10.2 % UnitedHealth Group 6.1 Intuitive Surgical 5.8 Thermo Fisher Scientific 4.6 Stryker 4.2 Danaher 3.7 Argenx 3.7 Merck 2.6 Boston Scientific 2.5 Vertex Pharmaceuticals 2.4 |
| Updated Prospectus Web Address | www.troweprice.com/paperless |
| C000005449 | |
| Shareholder Report [Line Items] | |
| Fund Name | Health Sciences Portfolio |
| Class Name | Health Sciences Portfolio - II Class |
| Trading Symbol | QAAHBX |
| Shareholder Report Annual or Semi-Annual | Annual Shareholder Report |
| Additional Information [Text Block] | You can find the fund’s prospectus, financial information on Form N‑CSR (which includes required tax information for dividends), holdings, proxy voting information, and other information at www.troweprice.com/prospectus info troweprice.com |
| Material Fund Change Notice [Text Block] | |
| Additional Information Phone Number | 1‑800‑638‑5660 |
| Additional Information Email | info@troweprice.com</span>" id="sjs-B48"><span style="box-sizing: border-box; color: rgb(0, 0, 0); display: inline; flex-wrap: nowrap; font-size: 13.3333px; font-weight: 400; grid-area: auto; line-height: 17.3333px; margin: 0px; overflow: visible; text-align: justify;">info@troweprice.com</span> |
| Additional Information Website | www.troweprice.com/prospectus |
| Expenses [Text Block] | What were the fund costs for the last year? Costs of a $10,000 investment Costs paid as a percentage of a $10,000 investment Health Sciences Portfolio - II Class $114 1.13% |
| Expenses Paid, Amount | $ 114 |
| Expense Ratio, Percent | 1.13% |
| Factors Affecting Performance [Text Block] | What drove fund performance during the past 12 months? The health care sector posted solid advances in the first nine months of 2024; however, these returns were diminished in the fourth quarter, leaving the group with modest gains for the year. The products and devices subsector was a bright spot as a handful of growth companies with exciting new product cycles led the segment higher. Despite facing heightened concerns around increased regulatory uncertainty at the end of the period, the pharmaceuticals segment was boosted by significant demand for a new class of diabetes and weight-loss drugs. The services subsector was the laggard in the space, largely driven by utilization pressures and heightened negative sentiment around the managed care industry. From an absolute perspective, the leading contributor to performance was the portfolio’s significant position in Eli Lilly. Shares of the pharmaceutical giant benefited from strong demand and improvements in capacity for its portfolio of incretin medicines, alongside several positive regulatory developments. Conversely, the leading detractor from absolute performance was Elevance Health. Shares of the insurer traded sharply lower at the end of the period due to multiple factors, including (1) a challenging Medicaid environment driving an uptick in utilization, (2) uncertainty around the health care agenda of the incoming presidential administration, and (3) worsening public sentiment toward the managed care space following the tragic murder of an industry executive. Our overarching investment philosophy remains focused on innovation, and we believe companies that are producing leading‑edge therapeutics and medical devices offer some of the market’s most attractive growth areas for investors with a multiyear horizon. |
| Performance Past Does Not Indicate Future [Text] | The fund’s past performance is not a good predictor of the fund’s future performance. |
| Average Annual Return [Table Text Block] | Average Annual Total Returns 1 Year 5 Years 10 Years Health Sciences Portfolio (Health Sciences Portfolio - II Class) 1.42 % 5.81 % 8.20 % Russell 3000 Index (Regulatory Benchmark) 23.81 13.86 12.55 Russell 3000 Health Care Index (Strategy Benchmark) 3.48 7.18 8.81 S&P 500 Index (Previous Benchmark) 25.02 14.53 13.10 The preceding line graph shows the value of a hypothetical $10,000 investment in the fund over the past 10 fiscal year periods or since inception (for funds lacking 10-year records). The fund’s performance information included in the line graph and table above is compared with a regulatory required index that represents an overall securities market (Regulatory Benchmark). In addition, the line graph and table may also include one or more indexes that more closely aligns to the fund's investment strategy (Strategy Benchmark(s)). Due to new SEC Rules on shareholder reporting the fund adopted a new broad-based securities market index, referred to as the Regulatory Benchmark. Market index returns do not include expenses, which are deducted from fund returns. The fund's total return figures reflect the reinvestment of dividends and capital gains, if any.Neither the fund’s returns nor the index returns reflect the deduction of taxes that a shareholder would pay on fund distributions or redemptions of fund shares. The fund’s past performance is not a good predictor of the fund’s future performance. |
| No Deduction of Taxes [Text Block] | Neither the fund’s returns nor the index returns reflect the deduction of taxes that a shareholder would pay on fund distributions or redemptions of fund shares. |
| Performance Table Market Index Changed [Text Block] | Due to new SEC Rules on shareholder reporting the fund adopted a new broad-based securities market index, referred to as the Regulatory Benchmark. |
| Updated Performance Information Location [Text Block] | Updated performance information can be found at www.troweprice.com. |
| Distribution of Capital [Text Block] | The fund's total return figures reflect the reinvestment of dividends and capital gains, if any. |
| AssetsNet | $ 664,924,000 |
| Holdings Count | Holding | 274 |
| Advisory Fees Paid, Amount | $ 5,427,000 |
| InvestmentCompanyPortfolioTurnover | 49.90% |
| Additional Fund Statistics [Text Block] | What are some fund statistics? Fund Statistics Total Net Assets (000s) $664,924 Number of Portfolio Holdings 274 |
| Holdings [Text Block] | Industry Other Biotechnology 27.4 % Major Pharmaceuticals 17.1 Implants 14.9 Life Sciences 10.9 Payors 10.9 Other Products & Devices 6.6 Major Biotechnology 6.5 Providers 1.8 Distribution 0.9 Other 3.0 |
| Largest Holdings [Text Block] | Top Ten Holdings Eli Lilly 10.2 % UnitedHealth Group 6.1 Intuitive Surgical 5.8 Thermo Fisher Scientific 4.6 Stryker 4.2 Danaher 3.7 Argenx 3.7 Merck 2.6 Boston Scientific 2.5 Vertex Pharmaceuticals 2.4 |
| Updated Prospectus Web Address | www.troweprice.com/paperless |
| Shareholder Report, Line Graph (Details) - USD ($) | Dec. 31, 2024 | Sep. 30, 2024 | Jun. 30, 2024 | Mar. 31, 2024 | Dec. 31, 2023 | Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2018 | Sep. 30, 2018 | Jun. 30, 2018 | Mar. 31, 2018 | Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 |
| Russell 3000 Index | |||||||||||||||||||||||||||||||||||||||||
| Account Value [Line Items] | |||||||||||||||||||||||||||||||||||||||||
| Account Value | $ 32,604 | $ 31,767 | $ 29,904 | $ 28,973 | $ 26,334 | $ 23,497 | $ 24,288 | $ 22,408 | $ 20,907 | $ 19,506 | $ 20,418 | $ 24,512 | $ 25,877 | $ 23,681 | $ 23,705 | $ 21,900 | $ 20,593 | $ 17,957 | $ 16,443 | $ 13,475 | $ 17,035 | $ 15,614 | $ 15,435 | $ 14,828 | $ 13,002 | $ 15,172 | $ 14,163 | $ 13,633 | $ 13,721 | $ 12,903 | $ 12,339 | $ 11,978 | $ 11,327 | $ 10,870 | $ 10,412 | $ 10,145 | $ 10,048 | $ 9,455 | $ 10,194 | $ 10,180 | $ 10,000 |
| Russell 3000 Index | |||||||||||||||||||||||||||||||||||||||||
| Account Value [Line Items] | |||||||||||||||||||||||||||||||||||||||||
| Account Value | 32,604 | 31,767 | 29,904 | 28,973 | 26,334 | 23,497 | 24,288 | 22,408 | 20,907 | 19,506 | 20,418 | 24,512 | 25,877 | 23,681 | 23,705 | 21,900 | 20,593 | 17,957 | 16,443 | 13,475 | 17,035 | 15,614 | 15,435 | 14,828 | 13,002 | 15,172 | 14,163 | 13,633 | 13,721 | 12,903 | 12,339 | 11,978 | 11,327 | 10,870 | 10,412 | 10,145 | 10,048 | 9,455 | 10,194 | 10,180 | 10,000 |
| Russell 3000 Health Care Index | |||||||||||||||||||||||||||||||||||||||||
| Account Value [Line Items] | |||||||||||||||||||||||||||||||||||||||||
| Account Value | 23,270 | 25,784 | 24,156 | 24,405 | 22,488 | 21,025 | 21,874 | 21,146 | 21,862 | 19,600 | 20,571 | 22,221 | 23,282 | 21,723 | 21,687 | 20,050 | 19,630 | 17,833 | 16,748 | 14,330 | 16,449 | 14,313 | 14,849 | 14,639 | 13,471 | 15,089 | 13,282 | 12,715 | 12,753 | 12,552 | 12,098 | 11,279 | 10,357 | 10,813 | 10,560 | 9,959 | 10,714 | 9,847 | 11,143 | 10,780 | 10,000 |
| S&P 500 Index | |||||||||||||||||||||||||||||||||||||||||
| Account Value [Line Items] | |||||||||||||||||||||||||||||||||||||||||
| Account Value | 34,254 | 33,448 | 31,589 | 30,291 | 27,399 | 24,531 | 25,361 | 23,322 | 21,696 | 20,170 | 21,206 | 25,276 | 26,494 | 23,863 | 23,724 | 21,856 | 20,585 | 18,355 | 16,850 | 13,979 | 17,386 | 15,940 | 15,674 | 15,027 | 13,223 | 15,290 | 14,195 | 13,724 | 13,829 | 12,967 | 12,411 | 12,039 | 11,351 | 10,933 | 10,527 | 10,275 | 10,138 | 9,471 | 10,123 | 10,095 | 10,000 |
| Russell 3000 Health Care Index | |||||||||||||||||||||||||||||||||||||||||
| Account Value [Line Items] | |||||||||||||||||||||||||||||||||||||||||
| Account Value | 23,270 | 25,784 | 24,156 | 24,405 | 22,488 | 21,025 | 21,874 | 21,146 | 21,862 | 19,600 | 20,571 | 22,221 | 23,282 | 21,723 | 21,687 | 20,050 | 19,630 | 17,833 | 16,748 | 14,330 | 16,449 | 14,313 | 14,849 | 14,639 | 13,471 | 15,089 | 13,282 | 12,715 | 12,753 | 12,552 | 12,098 | 11,279 | 10,357 | 10,813 | 10,560 | 9,959 | 10,714 | 9,847 | 11,143 | 10,780 | 10,000 |
| S&P 500 Index | |||||||||||||||||||||||||||||||||||||||||
| Account Value [Line Items] | |||||||||||||||||||||||||||||||||||||||||
| Account Value | $ 34,254 | $ 33,448 | $ 31,589 | $ 30,291 | $ 27,399 | $ 24,531 | $ 25,361 | $ 23,322 | $ 21,696 | $ 20,170 | $ 21,206 | $ 25,276 | $ 26,494 | $ 23,863 | $ 23,724 | $ 21,856 | $ 20,585 | $ 18,355 | $ 16,850 | $ 13,979 | $ 17,386 | $ 15,940 | $ 15,674 | $ 15,027 | $ 13,223 | $ 15,290 | $ 14,195 | $ 13,724 | $ 13,829 | $ 12,967 | $ 12,411 | $ 12,039 | $ 11,351 | $ 10,933 | $ 10,527 | $ 10,275 | $ 10,138 | $ 9,471 | $ 10,123 | $ 10,095 | $ 10,000 |
| Shareholder Report, Average Annual Return (Details) | 12 Months Ended | 60 Months Ended | 120 Months Ended |
| Dec. 31, 2024 | Dec. 31, 2024 | Dec. 31, 2024 | |
| Without Sales Load [Member] | C000005448 | |||
| Average Annual Return [Line Items] | |||
| Average Annual Return, Percent | 1.66% | 6.08% | 8.47% |
| Without Sales Load [Member] | C000005449 | |||
| Average Annual Return [Line Items] | |||
| Average Annual Return, Percent | 1.42% | 5.81% | 8.20% |
| Russell 3000 Index | |||
| Average Annual Return [Line Items] | |||
| Average Annual Return, Percent | 23.81% | 13.86% | 12.55% |
| Russell 3000 Index | |||
| Average Annual Return [Line Items] | |||
| Average Annual Return, Percent | 23.81% | 13.86% | 12.55% |
| Russell 3000 Health Care Index | |||
| Average Annual Return [Line Items] | |||
| Average Annual Return, Percent | 3.48% | 7.18% | 8.81% |
| S&P 500 Index | |||
| Average Annual Return [Line Items] | |||
| Average Annual Return, Percent | 25.02% | 14.53% | 13.10% |
| Russell 3000 Health Care Index | |||
| Average Annual Return [Line Items] | |||
| Average Annual Return, Percent | 3.48% | 7.18% | 8.81% |
| S&P 500 Index | |||
| Average Annual Return [Line Items] | |||
| Average Annual Return, Percent | 25.02% | 14.53% | 13.10% |
| Shareholder Report, Holdings (Details) | Dec. 31, 2024 |
| C000005448 | Eli Lilly | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 10.20% |
| C000005448 | UnitedHealth Group | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 6.10% |
| C000005448 | Intuitive Surgical | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 5.80% |
| C000005448 | Thermo Fisher Scientific | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 4.60% |
| C000005448 | Stryker | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 4.20% |
| C000005448 | Danaher | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 3.70% |
| C000005448 | Argenx | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 3.70% |
| C000005448 | Merck | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 2.60% |
| C000005448 | Boston Scientific | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 2.50% |
| C000005448 | Vertex Pharmaceuticals | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 2.40% |
| C000005448 | Other Biotechnology | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 27.40% |
| C000005448 | Major Pharmaceuticals | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 17.10% |
| C000005448 | Implants | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 14.90% |
| C000005448 | Life Sciences | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 10.90% |
| C000005448 | Payors | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 10.90% |
| C000005448 | Other Products & Devices | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 6.60% |
| C000005448 | Major Biotechnology | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 6.50% |
| C000005448 | Providers | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 1.80% |
| C000005448 | Distribution | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 0.90% |
| C000005448 | Other Holdings Grouping | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 3% |
| C000005449 | Eli Lilly | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 10.20% |
| C000005449 | UnitedHealth Group | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 6.10% |
| C000005449 | Intuitive Surgical | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 5.80% |
| C000005449 | Thermo Fisher Scientific | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 4.60% |
| C000005449 | Stryker | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 4.20% |
| C000005449 | Danaher | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 3.70% |
| C000005449 | Argenx | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 3.70% |
| C000005449 | Merck | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 2.60% |
| C000005449 | Boston Scientific | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 2.50% |
| C000005449 | Vertex Pharmaceuticals | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 2.40% |
| C000005449 | Other Biotechnology | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 27.40% |
| C000005449 | Major Pharmaceuticals | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 17.10% |
| C000005449 | Implants | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 14.90% |
| C000005449 | Life Sciences | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 10.90% |
| C000005449 | Payors | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 10.90% |
| C000005449 | Other Products & Devices | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 6.60% |
| C000005449 | Major Biotechnology | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 6.50% |
| C000005449 | Providers | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 1.80% |
| C000005449 | Distribution | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 0.90% |
| C000005449 | Other Holdings Grouping | |
| Holdings [Line Items] | |
| Percent of Net Asset Value | 3% |
